Active Ingredients
(in each tablet)
Guaifenesin 380mg
Pseudoephedrine HCl 60 mg
The following Structured Product Label (SPL) was submitted to the FDA by Poly Pharmaceuticals, Inc. for the product Poly-vent Ir (NDC 50991-212). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding active ingredients, purpose, uses, warnings, do not use, ask a doctor before use if you have, stop use and ask a doctor if:, if pregnant or breast feeding,, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
(in each tablet)
Guaifenesin 380mg
Pseudoephedrine HCl 60 mg
Expectorant
Nasal Decongestant
Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies:
depression, psychiatric, or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a
doctor or pharmacist before taking this product.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away.
| Adults and children 12 years of age and over: | 1 tablet every 4 hours, not to exceed 4 tablets in 24 hours, or as directed by a doctor. |
| Children age 6 to under 12 years of age: | ½ tablet every 4 hours, not to exceed 2 tablets in 24 hours, or as directed by a doctor. |
| Children 2 to under 6 years of age: | Consult a doctor. |
Tamper evident: do not use if tamper evident seal is broken or missing. Store at 15°-30°C (59°-86°F).
Poly Vent IR Tablets are a blue, oval, scored tablet debossed POLY 212 on one side, plain on the other.
FD&C Blue #2, Magnesium Stearate, Microcrystalline Cellulose, Sodium Starch Glycolate.
Call 1-800-882-1041.
Manufactured for:
Poly Pharmaceuticals
Quitman, MS 39355
(800) 882-1041 Rev. 04/13
* Please review the disclaimer below.